Expression of miR‑221 and miR‑489 in breast cancer patients and their relationship with prognosis

Li,Fanfan

doi:10.3892/ol.2019.11196

Expression of miR‑221 and miR‑489 in breast cancer patients and their relationship with prognosis

Authors:
- Fanfan Li
View Affiliations

Affiliations: Department of Breast Surgery, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China
Published online on: December 10, 2019 https://doi.org/10.3892/ol.2019.11196
Pages: 1523-1529
Copyright: © Li . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of miR‑221 and miR‑489 in breast cancer patients and their prognostic value were investigated. Sixty‑two breast cancer patients admitted to the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine for tumor surgery, from July 2014 to January 2016, were selected as the research group (RG), and 27 female adults who underwent physical examination during the same period were selected as the control group (CG). miR‑221 and miR‑489 expression levels in the blood samples of the breast cancer patients and the healthy female adults were detected by fluorescence reverse transcription‑quantitative PCR (RT‑qPCR), and the relationship of the expression levels of miR‑221 and miR‑489 with the disease prognosis was analyzed. The expression levels of miR‑221 and miR‑489 in the blood samples of breast cancer patients were 7.13±1.19 and 0.88±0.09, respectively, and those in the blood samples of healthy individuals were 5.82±0.84 and 1.01±0.12, respectively. The expression level of miR‑221 in the RG was significantly higher than that in the CG (P<0.01), while the expression level of miR‑489 in the RG was significantly lower than that in the CG (P<0.01). The area under the curve (AUC) of miR‑221 was 0.769, and the AUC of miR‑489 was 0.805. When AUC was equal to 0.88, the combined detection of the two had higher sensitivity and specificity than the single detection. The 3‑year survival rates of miR‑221 low‑expression group and miR‑489 high‑expression group were significantly higher than those of the miR‑221 high‑expression group and miR‑489 low‑expression group (P<0.05). miR‑221 expression was upregulated and miR‑489 expression was downregulated in blood samples of breast cancer patients, which had a certain impact on the patients survival. In the future, miR‑221 can be used as an effective indicator for diagnosis, treatment and prognosis of breast cancer.

View Figures

View References

1	Ghislain I, Zikos E, Coens C, Quinten C, Balta V, Tryfonidis K, Piccart M, Zardavas D, Nagele E, Bjelic-Radisic V, et al European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and Breast Cancer Group; EORTC Headquarters, : Health-related quality of life in locally advanced and metastatic breast cancer: Methodological and clinical issues in randomised controlled trials. Lancet Oncol. 17:e294–e304. 2016. View Article : Google Scholar : PubMed/NCBI
2	DeSantis CE, Ma J, Goding Sauer A, Newman LA and Jemal A: Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
3	Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 30:781–787. 2019. View Article : Google Scholar : PubMed/NCBI
4	Gao C, Li H, Zhuang J, Zhang H, Wang K, Yang J, Liu C, Liu L, Zhou C and Sun C: The construction and analysis of ceRNA networks in invasive breast cancer: A study based on The Cancer Genome Atlas. Cancer Manag Res. 11:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
5	Meng X, Müller V, Milde-Langosch K, Trillsch F, Pantel K and Schwarzenbach H: Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer. Oncotarget. 7:16923–16935. 2016. View Article : Google Scholar : PubMed/NCBI
6	Yu Y, Nangia-Makker P, Farhana L, G Rajendra S, Levi E and Majumdar AP: miR-21 and miR-145 cooperation in regulation of colon cancer stem cells. Mol Cancer. 14:982015. View Article : Google Scholar : PubMed/NCBI
7	Ying X, Wu Q, Wu X, Zhu Q and Wang X, Jiang L, Chen X and Wang X: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7:43076–43087. 2016. View Article : Google Scholar : PubMed/NCBI
8	Mukohyama J, Shimono Y, Dalerba P, Isobe T, Hu Q, Sahoo D, Shibuya N, Minami H, Mimori K, Kakeji Y, et al: Epigenetic regulation of colorectal cancer stem cells by the miR-221/QKI5 axis. Cancer Res. 78:4882018.
9	Fang Z, Zhong M, Wang Y, Yuan X, Guo H, Yao Y, Feng M, Chen J, Xiong J and Xiang X: miR-381 and miR-489 suppress cell proliferation and invasion by targeting CUL4B via the Wnt/β-catenin pathway in gastric cancer. Int J Oncol. 54:733–743. 2019.PubMed/NCBI
10	Xu D, Liu R, Meng L, Zhang Y, Lu G and Ma P: Long non-coding RNA ENST01108 promotes carcinogenesis of glioma by acting as a molecular sponge to modulate miR-489. Biomed Pharmacother. 100:20–28. 2018. View Article : Google Scholar : PubMed/NCBI
11	Vergara-Ortega DN, Sevilla-Reyes EE, Herrera-Ortiz A, Torres-Ibarra L, Salmerón J, Lazcano-Ponce E and Sánchez- Alemán MA: Real time PCR to evaluate HSV-2 shedding from anal and genital samples among men who have sex with men, living with HIV. J Med Virol. 90:745–752. 2018. View Article : Google Scholar : PubMed/NCBI
12	Singh SK, Singh S, Lillard JW Jr and Singh R: Drug delivery approaches for breast cancer. Int J Nanomedicine. 12:6205–6218. 2017. View Article : Google Scholar : PubMed/NCBI
13	Welch HG, Prorok PC, O'Malley AJ and Kramer BS: Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med. 375:1438–1447. 2016. View Article : Google Scholar : PubMed/NCBI
14	Burwinkel B, Cuk K, Zucknick M and Madhavan D: Circulating miRNAs as markers for breast cancer. US Patent 10,316,367. Filed June 21, 2013; issued June 11, 2019.
15	Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, et al: Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 379:111–121. 2018. View Article : Google Scholar : PubMed/NCBI
16	Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, et al MINDACT Investigators, : 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 375:717–729. 2016. View Article : Google Scholar : PubMed/NCBI
17	Malih S, Saidijam M and Malih N: A brief review on long noncoding RNAs: A new paradigm in breast cancer pathogenesis, diagnosis and therapy. Tumour Biol. 37:1479–1485. 2016. View Article : Google Scholar : PubMed/NCBI
18	Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G and Calin GA: MicroRNA therapeutics in cancer - an emerging concept. EBioMedicine. 12:34–42. 2016. View Article : Google Scholar : PubMed/NCBI
19	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
20	Acunzo M, Romano G, Wernicke D and Croce CM: MicroRNA and cancer - a brief overview. Adv Biol Regul. 57:1–9. 2015. View Article : Google Scholar : PubMed/NCBI
21	Reddy KB: MicroRNA (miRNA) in cancer. Cancer Cell Int. 15:382015. View Article : Google Scholar : PubMed/NCBI
22	Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, et al: MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 518:107–110. 2015. View Article : Google Scholar : PubMed/NCBI
23	Lou W, Liu J, Gao Y, Zhong G, Chen D, Shen J, Bao C, Xu L, Pan J, Cheng J, et al: MicroRNAs in cancer metastasis and angiogenesis. Oncotarget. 8:115787–115802. 2017. View Article : Google Scholar : PubMed/NCBI
24	Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, et al: miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. J Exp Clin Cancer Res. 37:942018. View Article : Google Scholar : PubMed/NCBI
25	Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J, Zhou L, Zheng SS and Jiang B: miR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer. Clin Transl Oncol. 20:703–712. 2018. View Article : Google Scholar : PubMed/NCBI
26	Chen X, Wang YW, Xing AY, Xiang S, Shi DB, Liu L, Li YX and Gao P: Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer. J Pathol. 239:459–472. 2016. View Article : Google Scholar : PubMed/NCBI
27	Roscigno G, Quintavalle C, Donnarumma E, Puoti I, Diaz-Lagares A, Iaboni M, Fiore D, Russo V, Todaro M, Romano G, et al: miR-221 promotes stemness of breast cancer cells by targeting DNMT3b. Oncotarget. 7:580–592. 2016. View Article : Google Scholar : PubMed/NCBI
28	Patel Y, Shah N, Lee JS, Markoutsa E, Jie C, Liu S, Botbyl R, Reisman D, Xu P and Chen H: A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth. Oncotarget. 7:18295–18308. 2016. View Article : Google Scholar : PubMed/NCBI
29	Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu Y, Zhang CY, Zen K and Gu H: Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression. Sci Rep. 6:257982016. View Article : Google Scholar : PubMed/NCBI
30	Ye Z, Hao R, Cai Y, Wang X and Huang G: Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumour Biol. 37:4509–4515. 2016. View Article : Google Scholar : PubMed/NCBI